Litigation Details for BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)
✉ Email this page to a colleague
BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)
Docket | ⤷ Sign Up | Date Filed | 2021-04-26 |
Court | District Court, D. New Jersey | Date Terminated | |
Cause | 15:25 Clayton Act | Assigned To | |
Jury Demand | Plaintiff | Referred To | |
Patents | 6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,668,730; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION
Biologic Drugs cited in BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2020-07-21 | 1 | 28-Aug- preventing the ’501 Patent 6,045,501 4-Apr-00 …800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, and the ’622 Patent. 96 …800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, and the ’622 Patent. 101…its ’517 Patent, ’720 Patent, ’977 Patent, ’784 Patent, ’740 Patent, ’800 Patent, ’217 Patent, ’569 Patent…Patent, ’886 Patent, ’717 Patent, ’498 Patent, ’531 Patent, ’095 Patent, ’120 Patent, ’621 Patent, and the | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |